# Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke

> **NCT06202378** · PHASE2 · COMPLETED · sponsor: **Shanghai Hutchison Pharmaceuticals Limited** · enrollment: 270 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** 3 ampoules of SHPL-49 Injection
- **DRUG:** 6 ampoules of SHPL-49 Injection
- **DRUG:** 0.9% Sodium Chloride Injection

## Key facts

- **NCT ID:** NCT06202378
- **Lead sponsor:** Shanghai Hutchison Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-29
- **Primary completion:** 2024-11-26
- **Final completion:** 2024-12-16
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2025-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06202378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06202378, "Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06202378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*